NEW YORK (GenomeWeb News) – Omicia said today that it intends to use funds from a recently closed $6.8 million Series A financing round led by Artis Ventures to expand its marketing reach and to optimize its whole-genome interpretation offering.

Other investors in the round included Acadia Woods Partners, Bay City Capital, Buchanan Investments, and Casdin Capital. As part of their investment, Tad Buchanan, principal of Buchanan Investments, and William Gerber from Bay City Capital will also join Omicia's board of directors, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease. 

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.